This is an advertisement
by on Jan 31 2012Dangerous Drugs, Heart Cholesterol Hypertension
Novartis Pharmaceuticals Canada Inc. has issued new safety information for the blood pressure drug Tekturna.
According to Health Canada, the new safety information comes after a clinical study indicated a higher occurrence of strokes, hyperkalemia, serious renal complications and hypotension in patients who used Tekturna.
The health issues were linked to, aliskren, a component of Tekturna and other high blood pressure drugs. In Canada the drug is sold under the brand names Rasilez and Rasilez HTC.
Novartis is advising patients with type 2 diabetes to refrain from taking Tekturna in combination with other drugs, such as angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) for the treatment of hypertension.
If you or a loved one has been harmed by a dangerous drug such as Tekturna, contact Sokolove Laws for a free legal consultation and to learn about your options.
See a complete list of case types we handle »